In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma Dealmaking Quarterly Statistics, Q4 2012

A look at financing, M&A, and alliance activity October – December 2012

Executive Summary

At $4.2 billion, biopharma financing in Q4 2012 showed a 36% increase over Q3 with FOPOs again dominating as the most popular deal type. With 34 finalized biopharma M&As, Q4 was the most active quarter of all 2012 for acquisitions. The 108 biopharma alliances completed had a combined potential deal value of almost $2 billion; Johnson & Johnson, with seven tie-ups, was the busiest pharmaco during Q4.

Advertisement

Related Content

Ultragenyx Raises $75 Million Series B, Prepares For A 2014 IPO
Ironwood Adds A China Wrinkle To Regional Deal Strategy
Reckitt’s Schiff Buy Reflects Nutritional Industry “On Fire”
Sanofi And Selecta To Partner On Immunotherapies For Life-Threatening Allergies
Intarcia Forgoes Partnerships, Raises $210M In Equity And Debt Instead
Forest Takes Over Namenda Lifecycle-Management Project In Deal With Adamas
Ziarco Picks Up Pfizer Assets, Series A Round
Celgene To Collaborate With VentiRx On TRL8 Receptor Agonist For Cancer
Cinven's Mercury Pharma Buy Could Spur European Specialty Consolidation
Schiff Nutrition Enlists Airborne For Sortie Into Immune Support

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003996

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel